DeutschNewstral
Article
bizjournals.com on 2021-03-23 12:11
Cambridge biotech taps Gilead's virology drug chief as its next CEO
Related news
- Gilead's virology drug head to take East Coast biotech's CEO postbizjournals.com
- Gilead's CEO is remaking the biotech — and he's looking for partnersbizjournals.com
- Cambridge startup taps former LogMeIn exec as CEObizjournals.com
- Boston biotech takes aim at Gilead's market: An HIV curebizjournals.com
- 'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointmentbizjournals.com
- This Cambridge biotech CEO just bought an $8M condo in Millennium Towerbizjournals.com
- Cambridge startup taps Constant Contact's former CEO as chief product officerbizjournals.com
- Cambridge biotech delivers coronavirus vaccinebizjournals.com
- Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and morebizjournals.com
- Giant pharma company, small biotech take aim at Gilead's market: HIV curebizjournals.com
- Biotech startup expands from Cambridge to Watertownbizjournals.com
- Cambridge biotech to return its PPP loanbizjournals.com
- Cambridge biotech relocates to West Coastbizjournals.com
- Cambridge biotech plans manufacturing hub in Marylandbizjournals.com
- Cambridge biotech Werewolf gets $72M funding roundbizjournals.com
- Health Care Digest: Where were the women in Gilead's CEO search — and morebizjournals.com
- Gilead's CEO gets pay bump as cancer drug strategy hits snagsbizjournals.com
- Picture this: Fujifilm invests in Cambridge biotech startupbizjournals.com
- Biotech wunderkind Vivek Ramaswamy opens first Cambridge outpostbizjournals.com
- Eli Lilly will pay $960M for migraine-focused Cambridge biotechbizjournals.com